Management of inflammatory bowel disease during COVID-19 pandemic. A practical review

From mid-December of 2019 a newly diagnosed Corona virus with a highly human to human transmission rate was discovered in china which rapidly involved many countries and became pandemic. Although most infected cases are mild but this virus can cause severe lung injury which lead to severe mortality and morbidity. The mortality rate of this virus is high in immunosuppressed patient or with previous medical disorder. Many Inflammatory bowel disease patient are using immunosuppressive or immunomodulating agents which has raised the concern of severe disease in these patients. In this review we are going to discuss about treatment challenges in these patients.